Gianluca Matteoli

@gianlucamatteoli.bsky.social

Prof. Gianluca Matteoli PI Mucosal Immunology lab Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven Advancing innovative therapies for IBD by unraveling stromal-immune system interactions.

Every €1 the EU invests in research can yield up to €11 in growth by 2045. With €43 billion from Horizon Europe, we’ve backed 15,000+ projects – from antibiotics to the transition. This year we’ll put in over €7.3 billion to meet Europe’s challenges. For everyone to benefit ↓ europa.eu/!WHpGGg

A stylised image on a dark blue background, with "€1 invested in research," alongside a hand wearing a light blue glove holding a stylised euro. On the right-hand side is the text, "€11 in economic growth by 2045," with another gloved hand placing a pile of stylised coins. In the bottom right corner sits the emblem of the European Union.

Fantastic story showcasing the full strength of @KU_Leuven — from cutting-edge basic science to real-world exploitation. A true example of how academic excellence can drive meaningful impact on health! @kuleuvenuniversity.bsky.social

Nature Reviews Microbiology@natrevmicro.nature.com · last yr.

#weekendreading🔬📑 A coronavirus assembly inhibitor that targets the viral membrane protein @nature.com #microsky www.nature.com/articles/s41...

Buongiorno from the @fibrotarget.bsky.social General Assembly meeting in Milan! It’s been an exciting start to the meeting we’ve already covered advancements in #fibrosis biomarker characterisation, imaging and how to quantify this and began laying the foundation for an upcoming clinical trial!

FIBROTARGET@fibrotarget.bsky.social · last yr.

FIBROTARGET GAM: Day 1 at Humanitas University in Milan Day 1 highlights: ✅ Patient insights from EFCCA ✅ New fibrosis biomarker research 🔬 ✅ Cutting-edge imaging 🏥 ✅ Laying the groundwork for a clinical trial 🏆 More soon—stay tuned! 🔍

FIBROTARGET GAM: Day 1 at Humanitas University in Milan Day 1 highlights: ✅ Patient insights from EFCCA ✅ New fibrosis biomarker research 🔬 ✅ Cutting-edge imaging 🏥 ✅ Laying the groundwork for a clinical trial 🏆 More soon—stay tuned! 🔍

BildBild

It’s #MucosalMonday and time for another Mucosal Immunology Podcast episode! This month Cecilia Muglia discusses how colonic polyps in pediatric patients are handled - and what they mean for food allergy. Find it on your favorite platform, including: www.iheart.com/podcast/269-...

Mucosal Immunology Podcast | iHeart

Enjoy enlightening podcasts designed to keep the scientific community up to date with the latest breakthroughs in mucosal immunology. Each episode features cutting-edge research from the Mucosal Immun...

iheart.com

Come along for a fantastic feature interview hosted by @marionbrunck.bsky.social, another medical mystery @ashu-mangalam.bsky.social, and the latest #EmergingLeadersinMI research! #MucosalMonday

Mucosal Immunology@mucosalimmunol.bsky.social · 2y ago

It’s #MucosalMonday and time for another Mucosal Immunology Podcast episode! This month Cecilia Muglia discusses how colonic polyps in pediatric patients are handled - and what they mean for food allergy. Find it on your favorite platform, including: www.iheart.com/podcast/269-...

🎉 600 Years of Excellence: KU Leuven 🎓🌌 This year, KU Leuven celebrates an extraordinary milestone: 600 years of knowledge, innovation, and impact. For six centuries, our university has been at the forefront of education, research, and societal advancement.

Bild

For 2025 I’m adding “Podcast Producer” to my CV! Be sure to download and follow the Mucosal Immunology Podcast from @mucosalimmunol.bsky.social and @societymucosalimm.bsky.social - available on all major podcast platforms.

Mucosal Immunology@mucosalimmunol.bsky.social · 2y ago

Our brand new Musocal Immunology Podcast is live! Episode 1 features @regisjoulia.bsky.social chatting with @marionbrunck.bsky.social, @ashu-mangalam.bsky.social, and more @societymucosalimm.bsky.social. Available on Spotify, Apple Podcasts, Amazon Music, and iHeart. www.iheart.com/podcast/269-...

The majority of people who responded to a poll in Nature say they’re now using Bluesky. They’re using it to connect with other scientists, keep up to date with other research or researchers, and promote their own research. 🧪

Bluesky’s science takeover: 70% of Nature poll respondents use platform

Roughly 6,000 readers answered our poll, with many declaring that Bluesky was nicer, kinder and less antagonistic to science than X.

go.nature.com